NATCO Pharma Limited revised earnings guidance for the fiscal year 2024. For this period, the company hopes to go past INR 12 billion PAT against INR 10 billion to INR 12 billion as previously expected, and expects sales will probably be a little less than INR 40 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,028 INR | +0.66% | +2.85% | +26.69% |
Apr. 09 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
Mar. 27 | NATCO Pharma Limited Announces Board Appointments | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.69% | 2.21B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- NATCOPHARM Stock
- News NATCO Pharma Limited
- NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024